EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy

Jung Yoon Park, Hyoung Moo Park, Jae-Yen Song iD, Kyung Jin Hwang, Mee-Ran Kim, Youn-Jee Chung

Journal of Clinical Medicine · 24.04.2025 · 14 (9) · 2958

DOI: 10.3390/jcm14092958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 24.04.2025. Verfasst von Jung Yoon Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic Univers…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Research Foundation for Gynecologic Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Osteoporosis is a major public health concern, due to its high risk of fractures and disability and associated medical costs. Romosozumab, an anabolic agent, has been approved for the treatment of osteoporosis in postmenopausal women at high risk of fractures. However, limited data exist on its long-term effects in the Korean population, particularly regarding its impact on bone mineral density (BMD), bone turnover markers, and body composition. This study aimed to evaluate the 12-month effects of romosozumab treatment on BMD, bone turnover markers, and body composition in postmenopausal Korean women with high-fracture-risk osteoporosis (T-scores ≤ −3.0). Additionally, the impact of concomitant postmenopausal hormone therapy (MHT) on BMD changes was assessed.

Methods

This multicenter, retrospective observational study included 50 postmenopausal women diagnosed with osteoporosis (T-scores ≤ −3.0) who received 12 monthly doses of romosozumab (210 mg) at two hospitals in Korea. Changes in BMD in the lumbar spine, femoral neck, and total hip were assessed using dual-energy X-ray absorptiometry (DXA). Bone turnover markers, including procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide of type 1 collagen (CTX), were measured at baseline and at 3, 6, and 12 months. Changes in body composition, including the skeletal muscle index (SMI), body mass index (BMI), and visceral adipose tissue (VAT), were also analyzed.

Results

After 12 months of romosozumab treatment, BMD significantly increased at the lumbar spine (14.65%), femoral neck (6.58%), and total hip (4.19%) (p < 0.05). P1NP levels increased significantly at 3 months (+37.9%), but returned to baseline at 6 months, while CTX levels continuously decreased (−27.8%) over 12 months. No significant changes were observed in SMI or BMI, but the VAT showed a slight decreasing trend (p < 0.05). Additionally, patients receiving concomitant MHT demonstrated a significantly greater increase in lumbar spine BMD compared to those receiving romosozumab alone (p < 0.05), while no significant differences were observed in femoral neck and total hip BMD.

Conclusions

This study demonstrated that 12 months of romosozumab treatment significantly improved BMD and bone turnover markers in postmenopausal Korean women with severe osteoporosis. The combination of romosozumab and MHT further enhanced lumbar spine BMD gains. These findings support the use of romosozumab as an effective treatment for high-risk osteoporotic fractures in postmenopausal Korean women, and suggest potential benefits of a combined therapeutic approach.

Schlagwörter

Stichwörter der Autor:innen

fractureosteoporosisromosozumabsclerostinsclerostin inhibition

Autor:innen und Institutionen

  • Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Ko…
  • Department of Obstetrics and Gynecology, Menopause Clinic Grace Women's Hospital, Goyang 10447, Republic of Korea.

ORCID-Profile: Jae-Yen Song

Förderung

  • Korea Research Foundation for Gynecologic Cancer

Zitieren

APA

Park, J. Y., Park, H. M., Song, J. Y., Hwang, K. J., Kim, M. R., & Chung, Y. J. (2025). Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy. Journal of Clinical Medicine, 14(9), 2958. https://doi.org/10.3390/jcm14092958

Vancouver

Park JY, Park HM, Song JY, Hwang KJ, Kim MR, Chung YJ. Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy. Journal of Clinical Medicine. 2025;14(9):2958. doi:10.3390/jcm14092958

BibTeX
@article{Park2025,
  author = {Park, Jung Yoon and Park, Hyoung Moo and Song, Jae-Yen and Hwang, Kyung Jin and Kim, Mee-Ran and Chung, Youn-Jee},
  title = {Real-World Evaluation of 12-Month Romosozumab Treatment in Korean Women with Severe Osteoporosis: Potential Synergy with Hormone Therapy},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {2958},
  doi = {10.3390/jcm14092958}
}
Kostenlos starten →